Cart
sales@molnova.com
Glembatumumab vedotin
CAS No. 1182215-65-1
Glembatumumab vedotin( —— )
Catalog No. M36588 CAS No. 1182215-65-1
Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate with potent anticancer effects, utilized in the study of triple negative breast cancer (TNBC).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 1091 | Get Quote |
|
| 5MG | 1444 | Get Quote |
|
| 10MG | 1881 | Get Quote |
|
| 25MG | 2732 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGlembatumumab vedotin
-
NoteResearch use only, not for human use.
-
Brief DescriptionGlembatumumab vedotin (CDX-011) is an antibody-drug conjugate with potent anticancer effects, utilized in the study of triple negative breast cancer (TNBC).
-
DescriptionGlembatumumab vedotin (CDX-011) is an ADC (antibody-drug conjugates (ADCs)) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects.
-
In VitroCell Viability Assay Cell Line:Osteosarcoma cell lines Concentration:1 μg/mL to 125 μg/mL Incubation Time:96 hours Result:Demonstrated osteosarcoma cytotoxic activity.
-
In VivoAnimal Model:Athymic mice (6-week-old) injected with human SK-MEL-2 and SK-MEL-5 melanoma cells Dosage:1.25 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, 40 mg/kg, 60 mg/kg, 80 mg/kg Administration:i.v.; every 4 days; for 16 days Result:Showed inhibition of tumor growth.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorMicrotubule Associated | Antibody-Drug Conjugates (ADCs)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1182215-65-1
-
Formula WeightApproximatel 149.16 kDa
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Christopher H Keir, et al. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer. Expert Opin Biol Ther. 2012 Feb;12(2):259-63. ?
molnova catalog
related products
-
β-CGRP, human TFA (1...
β-CGRP,human tissue is one of the calcitonin peptide, through complex behavior of calcitonin receptor like receptor (CRLR) - and receptor activity - modifying proteins (increased), and 1 and 300 - nM CRLR IC50s/RAMP1 and CRLR/RAMP2 cells.
-
Antitumor agent-19
Antitumor agent-19 is an antitumor agent targeting tumor-associated macrophages (TAMs) to serve as an effective TAMs modulator (EC50s: 17.18 μM and 18.87 μM in the RAW 264.7 cells and the BMDM cells).
-
Lumiflavine
Lumiflavine inhibits riboflavin uptake. It is produced by the photolysis of vitamin B2.
